MEDP - メッドペ―ス・ホ―ルディングス (Medpace Holdings Inc.) メッドペ―ス・ホ―ルディングス

 MEDPのチャート


 MEDPの企業情報

symbol MEDP
会社名 Medpace Holdings Inc (メッドペ―ス・ホ―ルディングス)
分野(sector) Health Care   ヘルスケア
産業(industry) Biotechnology: Commercial Physical_Biological Resarch  
業種 バイオテクノロジ―_メディカルリサ―チ   IT・通信(IT_Communications)
概要 事業概要 メッドペース・ホールディングス(Medpace Holdings Inc.)は臨床契約研究機関である。同社は臨床研究に基づく医薬品及び医療機器開発サービスを提供する。同社は医薬品、バイオ技術、および医療機器企業と協力して、臨床試験の開発・実施を行う。同社の麻薬開発サービスは、フルサービス第I-IV臨床開発サービスを主として、開発計画の設計、コーディネートされた中央検査室、プロジェクト管理、規制業務、臨床モニタリング、データ管理および分析、薬物動態検査の新薬申請の提出、および販売後のマーケティング臨床サポートを含む。また、バイオアナリティカルラボサービス、臨床ヒト薬理学、イメージングサービス、および臨床試験のための心電図読み取りのサポートを提供する。同社の事業は、主に北米、欧州、アジアに拠点を置く。   メッドペ―ス・ホ―ルディングスは米国の臨床試験受託企業。持株会社体制で、子会社を通じ臨床試験サ―ビスをバイオ医薬品企業や医療器具メ―カ―などの医療業界全体に提供する。主に心臓病、代謝性疾患、がん、内分泌系疾患、神経系疾患などに対する臨床試験をフェ―ズ1からフェ―ズ4まで実施する。本社はオハイオ州シンシナティ。   Medpace Holdings, Inc. engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance. The company was founded by August James Troendle in July 1992 and is headquartered in Cincinnati, OH.
本社所在地 5375 Medpace Way Cincinnati OH 45227 USA
代表者氏名 August J. Troendle 8月J.Troendle
代表者役職名 Chairman of the Board President Chief Executive Officer 取締役会長兼最高経営責任者(CEO)
電話番号 +1 513-579-9911
設立年月日 41671
市場名 NASDAQ National Market System
ipoyear 2016年
従業員数 2500人
url www.medpace.com
nasdaq_url https://www.nasdaq.com/symbol/medp
adr_tso
EBITDA EBITDA(百万ドル) 118.75300
終値(lastsale) 57
時価総額(marketcap) 2027575728
時価総額 時価総額(百万ドル) 1865.725
売上高 売上高(百万ドル) 556.54600
企業価値(EV) 企業価値(EV)(百万ドル) 232.587
当期純利益 当期純利益(百万ドル) 49.25000
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 Medpace Holdings Inc revenues increased 57% to $333.2M. Net income applicable to common stockholders increased 72% to $31M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Net income benefited from Amortization decrease of 22% to $14.8M (expense) Miscellaneous (expense) income net increase from $497K (expense) to $325K (income).

 MEDPのテクニカル分析


 MEDPのニュース

   Medpace (MEDP) Q1 Earnings Miss Estimates  2020/04/28 23:05:05 Zacks Investment Research
Medpace (MEDP) delivered earnings and revenue surprises of -1.30% and 1.24%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
   Medpace : Q1 2020 Earnings Presentation | MarketScreener  2020/04/28 20:38:10 MarketScreener
Q1 2020 FINANCIAL RESULTS APRIL 28, 2020 F O RWA R D L O O K I N G S TAT E M E N T S & … | April 28, 2020
   Medpace Holdings, Inc. Reports First Quarter 2020 Results  2020/04/28 20:15:00 Business Wire
CINCINNATI--(BUSINESS WIRE)--Medpace Holdings, Inc. (Nasdaq: MEDP) (“Medpace”) today announced financial results for the first quarter ended March 31, 2020. First Quarter 2020 Financial Results Revenue for the three months ended March 31, 2020 increased 15.0% to $230.9 million, compared to $200.7 million for the comparable prior-year period. On a constant currency organic basis, revenue for the first quarter of 2020 increased 15.2% compared to the first quarter of 2019. Backlog as of March 31,
   Medpace Holdings, Inc. to Report First Quarter 2020 Financial Results on April 28, 2020  2020/04/03 20:05:00 Business Wire
CINCINNATI--(BUSINESS WIRE)--Medpace Holdings, Inc. (Nasdaq:MEDP) (“Medpace”) today announced that it will report its first quarter 2020 financial results after the market close on Tuesday, April 28, 2020. The Company will host a conference call the following morning, Wednesday, April 29, 2020, at 9:00 a.m. ET to discuss these results. To participate in the conference call, dial 800-219-7113 (domestic) or 574-990-1030 (international) using the passcode 5203559. To access the conference call via
   Medpace Holdings, Inc. : Buying pressure | MarketScreener  2020/03/05 13:28:40 MarketScreener
Medpace Holdings, Inc. shares have recently benefited from a buyers' comeback, which was accompanied by a rise in volumes and volatility. This situation suggests a continuation of the upward dynamic. | March 5, 2020
   Medpace Holdings, Inc. to Report First Quarter 2020 Financial Results on April 28, 2020  2020/04/03 20:05:00 Business Wire
CINCINNATI--(BUSINESS WIRE)--Medpace Holdings, Inc. (Nasdaq:MEDP) (“Medpace”) today announced that it will report its first quarter 2020 financial results after the market close on Tuesday, April 28, 2020. The Company will host a conference call the following morning, Wednesday, April 29, 2020, at 9:00 a.m. ET to discuss these results. To participate in the conference call, dial 800-219-7113 (domestic) or 574-990-1030 (international) using the passcode 5203559. To access the conference call via
   Medpace Holdings, Inc. : Buying pressure | MarketScreener  2020/03/05 13:28:40 MarketScreener
Medpace Holdings, Inc. shares have recently benefited from a buyers' comeback, which was accompanied by a rise in volumes and volatility. This situation suggests a continuation of the upward dynamic. | March 5, 2020
   Medpace Holdings, Inc. Reports Fourth Quarter and Full Year 2019 Results  2020/02/24 21:15:00 Business Wire
CINCINNATI--(BUSINESS WIRE)--Medpace Holdings, Inc. (Nasdaq: MEDP) (“Medpace”) today announced financial results for the fourth quarter and full year ended December 31, 2019. Fourth Quarter and Full Year 2019 Financial Results Revenue for the three months ended December 31, 2019 increased 19.7% to $229.9 million, compared to $192.1 million for the comparable prior-year period. Revenue for the year ended December 31, 2019 increased 22.2% to $861.0 million, compared to $704.6 million for the year
   The Daily Biotech Pulse: FDA Approves Baudax Bio's Non-Opioid Pain Drug, Aerie Rallies On Q4 Results, D-Day For Esperion  2020/02/21 12:46:22 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks that hit 52-week highs on Feb. 20.) Akebia Therapeutics Inc (NASDAQ: AKBA ) Aptose Biosciences Inc (NASDAQ: APTO ) Arcturus Therapeutics Ltd (NASDAQ: ARCT ) Arcus Biosciences Inc (NYSE: RCUS ) BELLUS Health Inc (NASDAQ: BLU ) Bio-Rad Laboratories, Inc. Class A Common Stock (NYSE: BIO ) Calithera Biosciences Inc (NASDAQ: CALA ) Cue Biopharma Inc (NASDAQ: CUE ) DexCom, Inc. (NASDAQ: DXCM ) Fate Therapeutics Inc (NASDAQ: FATE ) GENMAB A/S/S ADR (NASDAQ: GMAB ) Grifols SA - ADR ADR Class B (NASDAQ: GRFS ) Halozyme Therapeutics, Inc. (NASDAQ: HALO ) Intuitive Surgical, Inc. (NASDAQ: ISRG ) Masimo Corporation (NASDAQ: MASI ) (announced its fourth-quarter results) Medpace Holdings Inc (NASDAQ: MEDP ) Mersana Therapeutics Inc (NASDAQ: MRSN ) Momenta Pharmaceuticals, Inc. (NASDAQ: MNTA ) Relmada Therapeutics Inc (NASDAQ: RLMD ) Repro-Med Systems, Inc. (NASDAQ: KRMD ) Revance Therapeutics Inc (NASDAQ: RVNC ) (announced $287.5-million debt offering) Revolution Medicines Inc (NASDAQ: RVMD ) (went public Feb. 13) Scpharmaceuticals Inc (NASDAQ: SCPH ) Soligenix, Inc.
   The Daily Biotech Pulse: Heron Pain Drug Review Extended, Disappointment For Teva In Tourette Syndrome Study  2020/02/20 12:06:25 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week highs on Feb. 19) Adverum Biotechnologies Inc (NASDAQ: ADVM ) Akebia Therapeutics Inc (NASDAQ: AKBA ) Anavex Life Sciences Corp (NASDAQ: AVXL ) Arcus Biosciences Inc (NYSE: RCUS ) Ascendis Pharma A/S (NASDAQ: ASND ) AVITA MED LTD/S ADR (NASDAQ: RCEL )(reacted to its half-yearly results) Bio-Rad Laboratories, Inc. Class A (NYSE: BIO ) Calithera Biosciences Inc (NASDAQ: CALA ) ChemoCentryx Inc (NASDAQ: CCXI ) Cue Biopharma Inc (NASDAQ: CUE )(said its therapeutic Immuno-STAT platform will be featured in a Merck & Co., Inc.'s (NYSE: MRK ) presentation at the Antigen Specific Immune Tolerance Drug Development Summit) DexCom, Inc. (NASDAQ: DXCM ) Fate Therapeutics Inc (NASDAQ: FATE ) Fulgent Genetics Inc (NASDAQ: FLGT ) GALAPAGOS NV/S ADR (NASDAQ: GLPG ) GENMAB A/S/S ADR (NASDAQ: GMAB )(reacted to its quarterly and full-year results) Grifols SA - ADR ADR Class B (NASDAQ: GRFS ) Insulet Corporation (NASDAQ: PODD ) Intuitive Surgical, Inc.
   Medpace Holdings, Inc. to Report First Quarter 2020 Financial Results on April 28, 2020  2020/04/03 20:05:00 Business Wire
CINCINNATI--(BUSINESS WIRE)--Medpace Holdings, Inc. (Nasdaq:MEDP) (“Medpace”) today announced that it will report its first quarter 2020 financial results after the market close on Tuesday, April 28, 2020. The Company will host a conference call the following morning, Wednesday, April 29, 2020, at 9:00 a.m. ET to discuss these results. To participate in the conference call, dial 800-219-7113 (domestic) or 574-990-1030 (international) using the passcode 5203559. To access the conference call via
   Medpace Holdings, Inc. : Buying pressure | MarketScreener  2020/03/05 13:28:40 MarketScreener
Medpace Holdings, Inc. shares have recently benefited from a buyers' comeback, which was accompanied by a rise in volumes and volatility. This situation suggests a continuation of the upward dynamic. | March 5, 2020
   Medpace Holdings, Inc. Reports Fourth Quarter and Full Year 2019 Results  2020/02/24 21:15:00 Business Wire
CINCINNATI--(BUSINESS WIRE)--Medpace Holdings, Inc. (Nasdaq: MEDP) (“Medpace”) today announced financial results for the fourth quarter and full year ended December 31, 2019. Fourth Quarter and Full Year 2019 Financial Results Revenue for the three months ended December 31, 2019 increased 19.7% to $229.9 million, compared to $192.1 million for the comparable prior-year period. Revenue for the year ended December 31, 2019 increased 22.2% to $861.0 million, compared to $704.6 million for the year
   The Daily Biotech Pulse: FDA Approves Baudax Bio's Non-Opioid Pain Drug, Aerie Rallies On Q4 Results, D-Day For Esperion  2020/02/21 12:46:22 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks that hit 52-week highs on Feb. 20.) Akebia Therapeutics Inc (NASDAQ: AKBA ) Aptose Biosciences Inc (NASDAQ: APTO ) Arcturus Therapeutics Ltd (NASDAQ: ARCT ) Arcus Biosciences Inc (NYSE: RCUS ) BELLUS Health Inc (NASDAQ: BLU ) Bio-Rad Laboratories, Inc. Class A Common Stock (NYSE: BIO ) Calithera Biosciences Inc (NASDAQ: CALA ) Cue Biopharma Inc (NASDAQ: CUE ) DexCom, Inc. (NASDAQ: DXCM ) Fate Therapeutics Inc (NASDAQ: FATE ) GENMAB A/S/S ADR (NASDAQ: GMAB ) Grifols SA - ADR ADR Class B (NASDAQ: GRFS ) Halozyme Therapeutics, Inc. (NASDAQ: HALO ) Intuitive Surgical, Inc. (NASDAQ: ISRG ) Masimo Corporation (NASDAQ: MASI ) (announced its fourth-quarter results) Medpace Holdings Inc (NASDAQ: MEDP ) Mersana Therapeutics Inc (NASDAQ: MRSN ) Momenta Pharmaceuticals, Inc. (NASDAQ: MNTA ) Relmada Therapeutics Inc (NASDAQ: RLMD ) Repro-Med Systems, Inc. (NASDAQ: KRMD ) Revance Therapeutics Inc (NASDAQ: RVNC ) (announced $287.5-million debt offering) Revolution Medicines Inc (NASDAQ: RVMD ) (went public Feb. 13) Scpharmaceuticals Inc (NASDAQ: SCPH ) Soligenix, Inc.
   The Daily Biotech Pulse: Heron Pain Drug Review Extended, Disappointment For Teva In Tourette Syndrome Study  2020/02/20 12:06:25 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week highs on Feb. 19) Adverum Biotechnologies Inc (NASDAQ: ADVM ) Akebia Therapeutics Inc (NASDAQ: AKBA ) Anavex Life Sciences Corp (NASDAQ: AVXL ) Arcus Biosciences Inc (NYSE: RCUS ) Ascendis Pharma A/S (NASDAQ: ASND ) AVITA MED LTD/S ADR (NASDAQ: RCEL )(reacted to its half-yearly results) Bio-Rad Laboratories, Inc. Class A (NYSE: BIO ) Calithera Biosciences Inc (NASDAQ: CALA ) ChemoCentryx Inc (NASDAQ: CCXI ) Cue Biopharma Inc (NASDAQ: CUE )(said its therapeutic Immuno-STAT platform will be featured in a Merck & Co., Inc.'s (NYSE: MRK ) presentation at the Antigen Specific Immune Tolerance Drug Development Summit) DexCom, Inc. (NASDAQ: DXCM ) Fate Therapeutics Inc (NASDAQ: FATE ) Fulgent Genetics Inc (NASDAQ: FLGT ) GALAPAGOS NV/S ADR (NASDAQ: GLPG ) GENMAB A/S/S ADR (NASDAQ: GMAB )(reacted to its quarterly and full-year results) Grifols SA - ADR ADR Class B (NASDAQ: GRFS ) Insulet Corporation (NASDAQ: PODD ) Intuitive Surgical, Inc.

 関連キーワード  (バイオテクノロジ―_メディカルリサ―チ 米国株 メッドペ―ス・ホ―ルディングス MEDP Medpace Holdings Inc.)

 twitter  (公式ツイッターやCEOツイッターなど)